OLMA

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Olema Pharmaceuticals Boosts Board with Strategic Appointment of Dr. Prakash Raman

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Olema Pharmaceuticals announced the appointment of Dr. Prakash Raman to its Board, enhancing its strategic direction as it advances pivotal Phase 3 trials for its lead drug, palazestrant. This comes as Olema prepares for significant data releases from its OPERA-01 trial later this year, indicating potential growth in its clinical pipeline.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Olema Pharmaceuticals named Prakash Raman, Ph.D., to its Board of Directors.</li><li>Raman&#039;s expertise will support pivotal Phase 3 program advancements.</li><li>Olema is preparing for data from OPERA-01 trial this fall.</li><li>Company&#039;s lead product, palazestrant, aims to redefine breast cancer treatment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>InduPro Therapeutics (N/A)</strong>: Dr. Raman was CEO, strengthening his expertise in oncology.</li><li><strong>Ribon Therapeutics (N/A)</strong>: Raman led this firm, enhancing his relevance to Olema&#039;s operations.</li><li><strong>Novartis (NVS)</strong>: Raman’s 14-year tenure gives him valuable industry connections.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it highlights key leadership changes that could impact Olema’s strategic direction and operational effectiveness, particularly in advancing clinical trials and partnerships.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Pivotal data from OPERA-01 trial is expected in Fall 2026.</li><li>Dr. Raman&#039;s extensive experience may enhance strategic partnerships.</li><li>Advancing palazestrant could drive significant future revenue growth.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Olema is advancing palazestrant through two Phase 3 trials.</li><li>OP-3136 is currently in a Phase 1 clinical study.</li><li>Dr. Raman brings over 20 years of industry experience.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying OLMA shares, poised for upside ahead of pivotal trial data in Fall.</p>
  </section>
</section>


<article>
    <h2>Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors</h2>
    <p>SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (NASDAQ:<a href="https://www.benzinga.com/quote/OLMA">OLMA</a>), a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for breast cancer and beyond, has announced the appointment of Prakash Raman, Ph.D., to its Board of Directors. This strategic move comes as the company progresses its lead program, palazestrant, through crucial clinical trials.</p>

    <section>
        <h3>Strategic Importance of the Appointment</h3>
        <p>"We are excited to welcome Prakash to Olema's Board of Directors at this important time for the Company as we advance our lead program, palazestrant, through two Phase 3 trials and earlier-stage combination studies," stated Sean P. Bohen, M.D., Ph.D., President and CEO of Olema Oncology. "His extensive experience across business development and portfolio strategy will be integral as we prepare for pivotal data from OPERA-01 this fall."</p>
    </section>

    <section>
        <h3>Dr. Raman's Extensive Background</h3>
        <p>Dr. Raman comes to Olema with over 20 years of experience in the biopharmaceutical industry. He currently serves as the CEO of InduPro Therapeutics, a company specializing in protein therapeutics for oncology and immunology. His prior roles include:</p>
        <ul>
            <li>President and CEO of Ribon Therapeutics, focusing on innovative small molecule drugs.</li>
            <li>Senior Partner and Chief Business Development Officer at Flagship Pioneering.</li>
            <li>Almost 14 years at Novartis in various roles, culminating as Vice President, Global Head of Novartis Institutes for Biomedical Research (NIBR) Business Development.</li>
        </ul>
        <p>Dr. Raman’s pivotal role at Novartis included guiding strategic collaborations and acquisitions in the immuno-oncology sector.</p>
    </section>

    <section>
        <h3>Vision for Olema Oncology</h3>
        <p>Upon joining the Board, Dr. Raman expressed his enthusiasm: "I am honored to join Olema's Board of Directors at this exciting stage in the Company's evolution. I look forward to collaborating with the Board and executive team to support the advancement of palazestrant and OP-3136, therapies with the potential to redefine the metastatic breast cancer treatment paradigm."</p>
        <p>Ian Clark, Chairman of Olema's Board, emphasized the significance of Dr. Raman's expertise: "His deep experience in the biopharmaceutical industry will be invaluable as Olema advances its programs and prepares for its next phase of growth."</p>
    </section>

    <section>
        <h3>About Olema Oncology</h3>
        <p>Headquartered in San Francisco, Olema Oncology is committed to transforming cancer treatment standards for patients with breast cancer and more. The company’s lead candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials. Additionally, Olema is developing OP-3136, a potent KAT6 inhibitor, now in a Phase 1 clinical study. For more information, visit <a href="https://www.olema.com">www.olema.com</a>.</p>
    </section>

    <section>
        <h3>Forward-Looking Statements</h3>
        <p>Statements in this news release that are not historical facts are forward-looking statements as defined by the Securities Act of 1933. These include statements regarding Olema's product candidates and the timing of clinical trials, which are subject to risks and uncertainties. Actual results may differ materially from those anticipated.</p>
    </section>

    <section>
        <h3>Contact Information</h3>
        <p><strong>Media and Investor Relations:</strong><br> 
        Courtney O'Konek<br> 
        Vice President, Corporate Communications<br> 
        Olema Oncology<br> 
        <a href="mailto:media@olema.com">media@olema.com</a></p>
    </section>
</article>

Olema Pharmaceuticals announced the appointment of Dr. Prakash Raman to its Board, enhancing its strategic direction as it advances pivotal Phase 3 trials for its lead drug, palazestrant. This comes as Olema prepares for significant data releases from its OPERA-01 trial later this year, indicating potential growth in its clinical pipeline.

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News